COST OF CARE COMPARISON OF ELRANATAMAB-BCMM AND TECLISTAMAB-CQYV IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

被引：0
|
作者：
Shah, B. [1 ]
Sandin, R. [2 ]
Liu, Y. [3 ]
Hu, Y. [4 ]
Schepart, A. [5 ]
Hughes, D. [6 ]
Hart, J. [7 ]
Hlavacek, P. [7 ]
机构：
[1] Boston Med Ctr, Boston, MA USA
[2] Pfizer AB, Stockholm, Sweden
[3] Cytel, Rotterdam, Netherlands
[4] Ingress Hlth Cytel Co, Riverside, CA USA
[5] Pfizer Inc, New York, NY USA
[6] Pfizer Inc, Dorchester, MA USA
[7] Pfizer Inc, Boston, MA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE14
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [21] Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study
    Dima, Danai
    Sannareddy, Aishwarya
    Ahmed, Nausheen
    Davis, James A.
    Shaikh, Hira
    Mahmoudjafari, Zahra
    Duco, Marissa
    Khouri, Jack
    Kaur, Gurbakhash
    Lochner, Jonathan
    Anwar, Faiz
    Afrough, Aimaz
    Valent, Jason
    Hashmi, Hamza
    Abdallah, Al-Ola
    BLOOD, 2023, 142
  • [22] Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol
    Bahlis, Nizar J.
    Trudel, Suzanne
    Maisel, Christopher
    Lee, Lisa X.
    Monge, Jorge
    Prada, Claudia Paba
    Larson, Sarah M.
    Koehne, Guenther
    Jethava, Yogesh
    Ma, Wei Dong
    De Nicolo, Cristina
    Perez-Cruz, Isabel
    BLOOD, 2023, 142
  • [23] Mezagitamab Induces Immunomodulatory Effect in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Abadier, Michael
    Estevam, Jose
    Berg, Deborah
    Fedyk, Eric Robert
    BLOOD, 2020, 136
  • [24] POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE
    Gomez, Hernando Marta
    Gironella, Merce
    Abella, Eugenia
    Cabezudo, Elena
    Motllo, Cristina
    Garcia, Antoni
    Sarra, Josep
    Mostacedo, Silvia
    Granell, Miquel
    Rosinol, Laura
    HAEMATOLOGICA, 2020, 105 : 13 - 14
  • [25] Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3
    Raab, M. S.
    Haenel, M.
    Raje, N.
    Leleu, X.
    Lesokhin, A.
    Mohty, M.
    Nooka, A. K.
    Leip, E.
    Conte, U.
    Viqueira, A.
    Manier, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 80 - 81
  • [26] A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma
    Mol, Isha
    Hu, Yannan
    Leblanc, Thomas W.
    Cappelleri, Joseph C.
    Chu, Haitao
    Nador, Guido
    Aydin, Didem
    Schepart, Alex
    Hlavacek, Patrick
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 660 - 668
  • [27] Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Stiff, Patrick J.
    Ibrahim, Emad
    Vallurupalli, Anusha
    Cull, Elizabeth H.
    Green, Damian J.
    Oliver, Kate
    Longcor, Jarrod
    BLOOD, 2019, 134
  • [28] Treatment patterns among patients with relapsed/refractory multiple myeloma (RRMM) in Taiwan
    Huang, Jeffrey Shang-Yi
    Wang, Ming-Chung
    Yeh, Su-Peng
    Chen, Tsai-Yun
    Teng, Chieh-Lin Jerry
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S188 - S189
  • [29] Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3
    Larson, Sarah Marie
    Bahlis, Nizar J.
    Maisel, Christopher
    Karlin, Lionel
    Yanovsky, Asya Varshavsky
    Leip, Eric
    Sullivan, Sharon T.
    Viqueira, Andrea
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE
    Oriol, A.
    Steinmetz, T.
    Patel, V
    Kutikova, L.
    Schmidt, N.
    Hennies, N.
    Thiess, A.
    Kostev, K.
    Leleu, X.
    VALUE IN HEALTH, 2019, 22 : S497 - S498
12345